On October 27, 2025, Eli Lilly announced a partnership with NBA legend Shaquille O'Neal to launch a nationwide campaign raising awareness about moderate-to-severe obstructive sleep apnea (OSA), targeting the 24 million affected U.S. adults, many of whom are overweight or living with obesity[3]. The initiative aims to educate the public and encourage diagnosis, but there is no indication this news has moved the stock significantly. LLY shares are down 0.48% to $821.48 in live trading, underperforming the broader market rally (S&P 500 +1.01%, NASDAQ +1.72%). The modest decline suggests LLY is not reacting strongly to today's news and may be influenced more by broader market sentiment or sector rotation rather than company-specific developments.
Lilly Partners with Shaquille O'Neal to Raise Awareness for Sleep Apnea
LLY
Related News
LLY
Eli Lilly Price Target Raised by Daiwa Securities Amid Strong Performance
LLY
Eli Lilly Stock Declines Amid Broader Market Gains and Valuation Debates
LLY
Eli Lilly Combination Therapy Achieves Superior Skin Clearance and Weight Loss in Phase 3b Psoriasis Trial
LLY
Eli Lilly and CSL Ink Licensing Deal for Anti-Inflammatory Drug
LLY